Core Points - Extendicare Inc. has completed the acquisition of nine "Class C" long-term care homes and a parcel of vacant land from Revera Inc. effective June 1, 2025 [1] - The total consideration for the transaction was approximately $60.3 million, consisting of $40.2 million in cash and the assumption of $20.1 million in liabilities [2] - The acquired homes include a total of 822 long-term care beds and 574 retirement beds across various locations in Ontario and Manitoba [3] Financial Details - The purchase price was funded from cash on hand, excluding transaction costs [2] - The liabilities assumed include government funding reimbursement obligations and committed capital maintenance project obligations [2] Operational Insights - Carlingview Manor is undergoing redevelopment into a new 320-bed long-term care home, owned by a joint venture between Extendicare and Axium [4] - Extendicare operates a network of 99 long-term care homes, providing approximately 11.2 million hours of home health care services annually [5] - The company employs around 26,500 qualified team members dedicated to delivering high-quality care [5]

Core Viewpoint - Semilux International Ltd. has received a delinquency notification from Nasdaq due to its failure to timely file its annual report for the year ended December 31, 2024, which may affect its compliance status with Nasdaq Listing Rule 5250(c)(1) [1][2][3] Group 1: Compliance and Reporting - The Company has 60 calendar days from the receipt of the Deficiency Letter to submit a plan to regain compliance with the Listing Rule [2] - Nasdaq may grant an extension of up to 180 calendar days from the due date of the Annual Report, potentially until November 11, 2025, for the Company to regain compliance [2] - The delay in filing the Annual Report is primarily due to the need for additional time to finalize financial statements and prepare the report [3] Group 2: Impact on Listing - The Deficiency Letter does not have an immediate impact on the listing of the Company's ordinary shares on the Nasdaq Capital Market [4] - The announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of deficiency notifications [4] Group 3: Company Overview - Semilux is based in the Cayman Islands and operates through its subsidiaries, including Taiwan Color Optics, Inc., which specializes in optical and 3D sensing technology [5] - The Company focuses on the customization, design, and supply of optical components for various industries, including autonomous driving and intelligent lighting [5] - TCO's products are used in applications such as automotive laser headlight systems and light detection and autonomous driving systems (LiDAR) [5]

Core Insights - Nxera Pharma's partner, Neurocrine Biosciences, has initiated the Phase 3 registrational program for NBI-1117568 as a potential treatment for schizophrenia, resulting in a $15 million payment to Nxera, which will be recognized as revenue in Q2 2025 [1][2] Company Overview - Nxera Pharma is a technology-powered biopharma company focused on developing specialty medicines to address unmet medical needs in Japan and globally [3] - The company has established a new-generation commercial business in Japan, aiming to develop and commercialize innovative medicines in a growing market [3] Pipeline and Research - Nxera is advancing a pipeline of over 30 active programs, utilizing its NxWave™ discovery platform, targeting major unmet needs in neurology/neuropsychiatry, metabolic diseases, and immunology [4] - The Phase 3 study for NBI-1117568 will enroll approximately 280 patients and aims to evaluate the drug's efficacy through the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression of Severity (CGI-S) scale [2]

Core Insights - Ascentage Pharma has presented promising clinical data for its MDM2-p53 inhibitor alrizomadlin (APG-115) at the ASCO Annual Meeting, indicating its potential as a treatment for advanced adenoid cystic carcinoma (ACC) and other solid tumors [1][2][3] Company Overview - Ascentage Pharma is a global biopharmaceutical company focused on addressing unmet medical needs in cancer treatment, with a pipeline that includes innovative drug candidates targeting apoptosis pathways [9][10] Clinical Study Highlights - The Phase II study of alrizomadlin demonstrated an objective response rate (ORR) of 16.7% and a disease control rate (DCR) of 100% in patients with advanced ACC [4][13] - In combination with PD-1 inhibitor toripalimab, alrizomadlin showed favorable antitumor activity in malignant peripheral nerve sheath tumor (MPNST), biliary-tract cancer (BTC), and liposarcoma (LPS) [3][4][13] - Notably, two patients with MPNST achieved long-term responses lasting over 60 and 96 weeks, respectively, when treated with the combination regimen [4][13] Safety and Efficacy Data - In the monotherapy arm, 33.3% of patients experienced grade 3 or higher treatment-related adverse events (TRAEs), while 12.5% experienced serious adverse events [13] - In the combination arm, 44.4% of patients reported grade 3 or higher TRAEs, with 29.6% experiencing treatment-related serious adverse events [13] Future Directions - The company aims to accelerate clinical programs to provide novel treatment options for patients globally, emphasizing the unmet clinical needs in both China and worldwide [4][12]

Core Insights - Ascentage Pharma presented promising data on its investigational Bcl-2 inhibitor, lisaftoclax (APG-2575), in combination with azacitidine for treating treatment-naïve or prior venetoclax-exposed myeloid malignancies at the ASCO Annual Meeting [1][2][3] Company Overview - Ascentage Pharma is a global biopharmaceutical company focused on addressing unmet medical needs in cancer treatment, with a pipeline that includes apoptosis-targeted therapies [13][16] - The company has been participating in the ASCO Annual Meeting for eight consecutive years, showcasing its commitment to advancing cancer therapies [2] Study Details - The Phase Ib/II study of lisaftoclax enrolled 103 patients with treatment-naïve or relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) as of April 2025 [3][4] - The study highlighted the antitumor activity and manageable tolerability of lisaftoclax, particularly in patients who were refractory to venetoclax, indicating its potential to overcome drug resistance [5][11] Efficacy Results - Among 28 venetoclax-refractory patients, the overall response rate (ORR) was 31.8%, with 22.8% achieving complete response (CR) or CR with incomplete hematologic recovery (CRi) [14] - In newly diagnosed AML patients, the ORR was 83.3%, with 33.3% achieving CR/CRi [14] - For patients with relapsed/refractory MDS/chronic myelomonocytic leukemia (CMML), the ORR was 50%, with 27.3% achieving CR [14] Safety Profile - Lisaftoclax combined with azacitidine was well tolerated, with common adverse events primarily being hematologic and manageable [10][11] - Non-hematologic toxicity was uncommon, indicating a favorable safety profile for the combination therapy [10] Regulatory Progress - The New Drug Application (NDA) for lisaftoclax for treating relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) was accepted with Priority Review designation in China [4][16] - Lisaftoclax is currently being evaluated in four global registrational Phase III studies for major indications including CLL/SLL, AML, and MDS [4][16]

Core Insights - DeFi Development Corp. reported a record-setting May 2025, highlighting advancements in validator infrastructure, treasury growth, and strategic integrations [1][2][3] Group 1: Company Strategy and Operations - The company has adopted a treasury policy focused on accumulating and compounding Solana (SOL), providing investors with direct economic exposure to SOL while participating in the Solana ecosystem's growth [4] - DeFi Development Corp. operates its own validator infrastructure, generating staking rewards and fees from delegated stake, and is actively engaged in decentralized finance (DeFi) opportunities [4] - The company aims to differentiate itself from other crypto vehicles by compounding SOL exposure per share over time, establishing itself as a pioneering Solana treasury strategy [3] Group 2: Recent Achievements - In May 2025, DeFi Development Corp. achieved its largest monthly SOL purchase, reinforcing its strategy to build a leading publicly traded Solana treasury [8] - The company announced a validator partnership with Bonk, Solana's largest memecoin community, expanding its network of revenue-generating validators [8] - A letter of intent was signed with Kamino Finance, the largest DeFi lending protocol on Solana, to integrate the dfdvSOL liquid staking token [8] - As of May 31, 2025, the company's treasury held a record 621,313 SOL, marking its largest holding to date [8]

Core Viewpoint - Parex Resources Inc. has appointed Alberto Consuegra as an independent director to its Board of Directors, bringing over 30 years of experience in the energy sector, particularly in Colombia [1][2][3] Company Overview - Parex Resources Inc. is one of the largest independent oil and gas companies in Colombia, focusing on sustainable conventional production [4] - The company's headquarters are located in Calgary, Canada, with an operating office in Bogotá, Colombia [4] - Parex shares are traded on the Toronto Stock Exchange under the symbol PXT [4] New Appointment Details - Alberto Consuegra's appointment is effective June 1, 2025 [2] - He previously served as the Chief Operating Officer of Ecopetrol and acted as the interim Chief Executive Officer [2] - Consuegra has held various executive positions at Cenit Transporte y Logística de Hidrocarburos S.A.S., Equion Energia Ltd., and BP Exploration [2] Educational Background - Consuegra graduated with a civil engineering degree from Universidad de Cartagena and holds a master's degree in civil engineering from Texas A&M University [3]

Core Insights - Kura Oncology and Kyowa Kirin announced positive pivotal results from the KOMET-001 Phase 2 trial of ziftomenib for relapsed/refractory NPM1-mutant AML patients, with a complete remission (CR) plus CR with partial hematological recovery (CRh) rate of 23% [1][3][2] - The trial demonstrated consistent efficacy across various pre-specified subgroups, indicating the potential of ziftomenib as a treatment option for heavily pre-treated patients [1][4][2] - Ziftomenib has a favorable safety profile, with limited myelosuppression and a low discontinuation rate due to treatment-related adverse events [1][5][7] Company Overview - Kura Oncology is a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, with ziftomenib being the first investigational therapy to receive Breakthrough Therapy Designation from the FDA for R/R NPM1-m AML [9] - The company has a strategic collaboration with Kyowa Kirin to develop and commercialize ziftomenib, with ongoing clinical trials evaluating its efficacy in combination with current standards of care [9][10] Clinical Trial Details - The KOMET-001 Phase 2 trial included 92 adult patients with a median age of 69, with 33% having received three or more prior lines of therapy [2][3] - Among the patients achieving CR/CRh, 63% were minimal residual disease (MRD)-negative, highlighting the treatment's potential effectiveness [3][4] Safety and Tolerability - The safety profile of ziftomenib showed that treatment-related adverse events led to discontinuation in only 3% of patients, with differentiation syndrome being the most common adverse event [5][6][7] - The absence of clinically significant QTc prolongation and effective management of differentiation syndrome further support ziftomenib's favorable benefit-risk profile [7][6] Future Outlook - The FDA has set a PDUFA target action date of November 30, 2025, for the New Drug Application (NDA) of ziftomenib, indicating a potential first approval for a once-daily oral menin inhibitor for this patient population [1][2] - Kura Oncology is hosting a virtual investor event to discuss the trial results and future plans for ziftomenib [8]

SYDNEY, June 02, 2025 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Mark Gossington as a Senior Managing Director in the Risk & Investigations practice within the firm’s Forensic and Litigation Consulting segment. Mr. Gossington, who is based in Sydney, brings more than 25 years of experience leading complex risk engagements and remediation programmes that have helped companies strengthen resilience under regulatory scrutiny, recover from misconduct issues and build ...

Company resumed trading under its existing symbol "MINM" HONG KONG, June 2, 2025 /PRNewswire/ -- FiEE, Inc. (NASDAQ:MINM) ("FiEE, Inc." or the "Company"), a technology company integrating IoT, connectivity and AI to redefine brand management solutions in the digital era, commenced the trading of its common stock on Monday, June 2, 2025 on the Nasdaq Capital Market under the ticker symbol "MINM".With the vision of growing Key Opinion Leaders ("KOLs") in the market, FiEE, Inc. is currently strategically trans ...